Screener
Arcutis Biotherapeutics, Inc. ARQT Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Arcutis Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Arcutis Biotherapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:21 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001787306-26-000051
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Accounts payable | (5,923) | 863 |
| Accrued liabilities | 30,723 | 21,018 |
| Operating lease liabilities | (276) | (404) |
| Net cash provided by (used in) operating activities | 14,878 | (30,056) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Purchases of marketable securities | (127,744) | (89,262) |
| Proceeds from maturities and sales of marketable securities | 101,346 | 129,121 |
| Milestone payment for intangible asset | — | (10,000) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Arcutis Biotherapeutics, Inc.'s operating cash flow?
- Arcutis Biotherapeutics, Inc. (ARQT) reported operating cash flow of $12.64M in Q2 2026.
- What is the long-term trend for Arcutis Biotherapeutics, Inc.'s operating cash flow?
- Over 3 years (2021 to 2024), Arcutis Biotherapeutics, Inc.'s operating cash flow has grown at a -13.7% compound annual growth rate (CAGR), from -$174.63M to -$112.16M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Arcutis Biotherapeutics, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude